Establishment and characterization of an immature human megakaryoblastic cell line, MEG-A2

Leukemia. 1995 Feb;9(2):341-9.

Abstract

We have established a novel human megakaryoblastic cell line, designated as MEG-A2, from a patient with megakaryoblastic crisis of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia. MEG-A2 cells showed positive phenotypes for periodic acid Schiff and alpha-naphthylbutyrate esterase reactions, but were negative for myeloperoxidase and naphthol ASD chloroacetate esterase reactions. Flow cytometric analyses of cell surface markers revealed that MEG-A2 cells had a low level of GP IIb/IIIa expression as well as apparent expressions of CD4, CD7, CD13, CD33 and CD34 antigens, but no expression of GP Ib nor glycophorin A. Stimulation with phorbol 12-myristate 13-acetate (PMA) dramatically increased the expression of megakaryocyte-related markers such as HPL-3, J15, Pit-1, Y2/51 and AN51 in MEG-A2 cells. The PMA-stimulation also induced expression of platelet peroxidase (PPO) in MEG-A2 cells on electromicroscopic observation. Proliferative responses to granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) or erythropoietin were observed, and the expression of GP IIb/IIIa was increased by stimulation with GM-CSF, IL-3, erythropoietin and interleukin-6 (IL-6). Protein S mRNA expression was seen in cultured cells on Northern blot analysis. Expression of platelet factor 4 mRNA was induced in PMA-stimulated cells, and a marked accumulation of protein was observed in the culture medium. In conclusion, a new cell line, MEG-A2, belongs to the relatively immature megakaryocytic lineage and has markedly increased megakaryocytic characteristics with PMA stimulation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aneuploidy
  • Antigens, CD / analysis
  • Antigens, Differentiation / analysis
  • Base Sequence
  • Biomarkers, Tumor / analysis
  • Blast Crisis / pathology
  • Carboxylic Ester Hydrolases
  • Cell Division / drug effects
  • Fatal Outcome
  • Gene Expression Regulation, Leukemic / drug effects
  • Hematopoietic Cell Growth Factors / pharmacology
  • Hematopoietic Stem Cells / chemistry
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Megakaryocytes*
  • Molecular Sequence Data
  • Neoplasm Proteins / analysis
  • Neoplastic Stem Cells / chemistry
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / pathology*
  • Platelet Factor 4 / biosynthesis
  • Platelet Factor 4 / genetics
  • Platelet Membrane Glycoproteins / analysis
  • Protein S / biosynthesis
  • Protein S / genetics
  • Proto-Oncogene Proteins / biosynthesis
  • Proto-Oncogene Proteins / genetics
  • Receptors, Cytokine*
  • Receptors, Immunologic / biosynthesis
  • Receptors, Immunologic / genetics
  • Receptors, Thrombopoietin
  • Tetradecanoylphorbol Acetate / pharmacology
  • Tumor Cells, Cultured* / chemistry
  • Tumor Cells, Cultured* / drug effects
  • beta-Thromboglobulin / biosynthesis
  • beta-Thromboglobulin / genetics

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • Biomarkers, Tumor
  • Hematopoietic Cell Growth Factors
  • Neoplasm Proteins
  • Platelet Membrane Glycoproteins
  • Protein S
  • Proto-Oncogene Proteins
  • Receptors, Cytokine
  • Receptors, Immunologic
  • Receptors, Thrombopoietin
  • beta-Thromboglobulin
  • MPL protein, human
  • Platelet Factor 4
  • Carboxylic Ester Hydrolases
  • naphthylbutyrate esterase
  • Tetradecanoylphorbol Acetate